Diazinon

CAS RN:333-41-5

Laboratory

A) Monitor vital signs frequently. Institute continuous cardiac and pulse oximetry monitoring. Monitor for respiratory distress (i.e. bronchorrhea, bronchospasm) and for clinical evidence of cholinergic excess (i.e. salivation, vomiting, urination, defecation, miosis).
B) Determine plasma and/or red blood cell cholinesterase activities (plasma is generally more sensitive, but red cell correlates somewhat better with clinical signs and symptoms). Depression in excess of 50% of baseline is generally associated with cholinergic effects, in severe poisoning cholinesterase activity may be depressed by 90% of baseline. Correlation between cholinesterase levels and clinical effects in milder poisonings may be poor.
C) Obtain serial ECGs. Patients who develop a prolonged QTc interval or PVCs are more likely to develop respiratory insufficiency and have a worse prognosis.
D) Monitor electrolytes and serum lipase in patients with significant poisoning. Patients who have increased pancreatic enzyme concentrations are more likely to develop respiratory insufficiency and have a worse prognosis.
E) Monitor pulmonary function (i.e. forced vital capacity, expiratory volume in 1 second, negative inspiratory force) in symptomatic patients, may help anticipate need for intubation.
Find more information on this substance at: Hazardous Substances Data Bank , TOXNET , PubMed